$53.89
8.72% day before yesterday
Nasdaq, Sep 06, 10:15 pm CET
ISIN
US74006W1080
Symbol
PRAX
Sector
Industry

Praxis Precision Medicines Inc Stock price

$54.02
-1.17 2.12% 1M
-4.14 7.12% 6M
+31.74 142.46% YTD
+33.47 162.87% 1Y
-267.58 83.20% 3Y
-230.98 81.05% 5Y
-230.98 81.05% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-5.02 8.50%
ISIN
US74006W1080
Symbol
PRAX
Sector
Industry

Key metrics

Market capitalization $959.24m
Enterprise Value $609.31m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 344.24
P/S ratio (TTM) P/S ratio 541.94
P/B ratio (TTM) P/B ratio 2.29
Revenue growth (TTM) Revenue growth 20.97%
Revenue (TTM) Revenue $1.77m
EBIT (operating result TTM) EBIT $-132.70m
Free Cash Flow (TTM) Free Cash Flow $-94.20m
Cash position $351.88m
EPS (TTM) EPS $-10.27
P/E forward negative
P/S forward 649.10
EV/Sales forward 412.31
Short interest 10.50%
Show more

Is Praxis Precision Medicines Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Praxis Precision Medicines Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Praxis Precision Medicines Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Praxis Precision Medicines Inc forecast:

Buy
90%
Hold
10%

Financial data from Praxis Precision Medicines Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
1.77 1.77
21% 21%
100%
- Direct Costs 0.65 0.65
46% 46%
37%
1.12 1.12
348% 348%
63%
- Selling and Administrative Expenses 43 43
10% 10%
2,445%
- Research and Development Expense 90 90
18% 18%
5,079%
-132 -132
16% 16%
-7,460%
- Depreciation and Amortization 0.65 0.65
46% 46%
37%
EBIT (Operating Income) EBIT -133 -133
16% 16%
-7,497%
Net Profit -124 -124
21% 21%
-6,991%

In millions USD.

Don't miss a Thing! We will send you all news about Praxis Precision Medicines Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Praxis Precision Medicines Inc Stock News

Neutral
GlobeNewsWire
3 days ago
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present preclinical and clinical data from three of its epileps...
Neutral
GlobeNewsWire
5 days ago
Placebo-adjusted monthly motor seizure reduction of 46% during double-blind period Over 30% of patients achieved seizure freedom status while on relutrigine Meaningful gains observed in alertness, communication and seizure severity 75% reduction in median seizure rate seen for patients in the long-term extension Registrational phase of the EMBOLD study for SCN2A and 8A initiated BOSTON, Mass., ...
Neutral
GlobeNewsWire
5 days ago
BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will share the topline results from the Phase 2 EMBOLD study of r...
More Praxis Precision Medicines Inc News

Company Profile

Praxis Precision Medicines, Inc. is a clinical-stage genetic neuroscience company that develops therapies for patients and families affected by complex and debilitating brain disorders. The company was founded by Kiran Reddy, David Goldstein and Steven Petrou on September 22, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Marcio Souza
Employees 82
Founded 2015
Website www.praxismedicines.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today